Pages
Products

GMP plasmid Production for LV, AAV and in vivo CAR-T

Overview Solution Manufacturing Quality Control GMP Documentation

GMP plasmid DNA manufacturing tailored to viral vector production, with construct optimization, process development, scalable fermentation and quality-controlled release for lentiviral and AAV applications.

1–100 L

Fermentation scale

>1-5 g/L

Volumetric yield

≥90%

Supercoiled content

≤0.01 EU/µg

Endotoxin

Request a technical proposal

Why Plasmid Quality Matters for Vector Manufacturing

In cell and gene therapy, the plasmid is the first lot you release and the cheapest place to fix a problem. It is also where problems hide: a truncated ITR, 0.05 EU/µg of endotoxin, or one drifted base in a packaging gene. None of it shows up on a gel or a quick A260 reading — it surfaces months later as low titer, empty capsids or a failed release.

Titer that quietly drops

Nicked or linearized plasmid, or a packaging gene that no longer matches the reference, reduces transfection efficiency before any process parameter changes.

Empty capsids

ITRs are 145 bp palindromic repeats that delete during E. coli propagation. A truncated ITR still grows and still yields DNA — it just packages badly.

Release under pressure

Endotoxin, host DNA or identity failures force a repeat lot exactly when your vector slot is already booked. The recovery cost is schedule, not reagent.

Plasmid DNA Solutions for Different Downstream Applications

Different vector manufacturing platforms require different plasmid configurations and quality attributes. We tailor construct evaluation, process development and release strategies to the requirements of each program.

Lentiviral Vector Plasmids

Applications: Ex vivo CAR-T, TCR-T, and in vivo LV-delivered CAR

Lentiviral vector production commonly involves transfer, gag-pol, rev and envelope plasmids. Their sequence identity, concentration and topology should be consistently controlled to support reproducible multi-plasmid transfection.

Key Manufacturing Considerations

  • Sequence verification of individual plasmids.
  • Consistent DNA concentration and formulation across plasmid sets.
  • Supercoiled content and plasmid topology analysis.
  • LTR, RRE and other construct-specific sequence characterization.
  • Endotoxin and residual impurity control.

AAV Vector Plasmids

Applications: Gene therapy and AAV-delivered in vivo CAR-T

AAV manufacturing commonly uses an ITR-containing transfer plasmid, a rep/cap plasmid and a helper plasmid. Maintaining ITR integrity is a key consideration during plasmid propagation and manufacturing.

Key Manufacturing Considerations

  • ITR-compatible host strain selection.
  • Low-copy-number and controlled-temperature cultivation strategies, where appropriate.
  • ITR-specific integrity characterization.
  • Full-plasmid sequence identity assessment.
  • Control of plasmid topology and process-related impurities.

In Vivo CAR-T Programs

Applications: Vector-based AAV or targeted LV delivery

In vivo CAR-T programs require plasmid manufacturing strategies aligned with the selected delivery platform, such as AAV or lentiviral vectors. Construct design, vector compatibility, supply requirements and CMC documentation should be evaluated together.

Key Manufacturing Considerations

  • Delivery-platform-specific plasmid design and characterization.
  • ITR, LTR or other relevant regulatory-element integrity.
  • Scalable production and lot-to-lot consistency.
  • Stability studies and change-control documentation.
  • Technology transfer and long-term supply planning.

What decides the batch

Same platform, different critical attributes. Use this to check whether our release strategy matches the failure mode you are actually trying to avoid.

Program Plasmid set Attribute that decides performance How we control it Typical scale
Ex vivo CAR-T / TCR-T (LV) Transfer + gag-pol + rev + VSV-G Supercoiled fraction, packaging-gene fidelity, matched concentration across the set Four-plasmid co-release, full sequencing, low-copy rescue, DNase-free 100 mg – 1 g
AAV gene therapy ITR transgene + rep/cap + helper ITR integrity, backbone size, host DNA ITR-stabilising strains, low-copy expansion, ITR ≥95% release limit 100 mg – 2 g
In vivo CAR-T (AAV) ITR CAR cassette + capsid + helper ITR integrity at scale, lot-to-lot consistency, documentation depth Gram-scale campaign, ICH stability, DMF modules, change control 1 – 5 g
In vivo CAR-T (LV) Transfer + packaging + envelope Envelope and LTR fidelity, endotoxin, supply continuity Matched sets, backup capacity, tech transfer package 1 – 5 g

Scale ranges are indicative and depend on construct size, copy number and downstream vector demand. Minimum campaign starts at 1 L fermentation.

From Construct Rescue to GMP Release

You keep one project manager and one quality contact from intake to CoA. Construct feasibility is decided before any GMP material is committed, so surprises stay in the development phase where they are cheap.

Tech transfer

Send the existing plasmid and its documentation. We audit, qualify and scale what you already have.

Rescue & re-clone

Unstable, low-yield or oversized constructs re-cloned into a production backbone before GMP.

Design to GMP

Construct design, gene synthesis, strain selection and GMP manufacture in one accountable chain.

01

Construct intake & gap review

1–2 weeks

Sequence and restriction audit, strain compatibility, ITR/LTR stability risk, rescue plan and quotation.

02

Seed & strain optimisation

2–3 weeks

Growth and plasmid-stability screening, low-copy rescue, research-grade lot for downstream checks.

03

MCB / WCB establishment

3–4 weeks

Two-tier banking with identity, purity, viability and stability qualification; full documentation.

04

Process development & scale-up

2–4 weeks

Lysis, TFF and AEX/HIC development; yield and impurity DOE; scale-down model qualified.

05

GMP fermentation & purification

2–3 weeks

1–100 L single-use fermentation, closed processing, Grade A isolator fill-finish.

06

QC release & QA disposition

2–3 weeks

Full release panel, CoA, batch record review, stability initiation and shipment.

Indicative durations for a first-time program; stages 03–05 overlap where the construct allows. GMP manufacture and QC release alone typically run 4–6 weeks, consistent with our standard 1–2 month GMP delivery window for constructs with a qualified cell bank and established process. The confirmed schedule is issued with the quality agreement.

GMP Plasmid DNA Quality Control & Release

Plasmid quality is assessed through a combination of identity, structural integrity, purity, microbiological and physicochemical testing. Analytical methods and acceptance criteria are selected according to the plasmid construct, manufacturing process and intended downstream application.

Typical Quality Control Panel

Parameter Method Typical limit Why it matters downstream
Identity & structure Insert identity Sanger + NGS 100% match Correct transgene and regulatory element sequence
Restriction map RE digest Matches reference Structural integrity across the whole construct
AAV ITR integrity RE digest + sequencing ≥95% Packaging efficiency and full:empty ratio
LV LTR / RRE integrity Sequencing 100% match Titer and recombination-risk control
Physicochemical Appearance Visual inspection Clear, particle-free Particulate load entering transfection
Concentration UV A260 0.5–3.0 mg/mL, set per project Accurate molar ratios in multi-plasmid transfection
Supercoiled content HPLC / CGE ≥90.0% Transfection efficiency and vector genome delivery
A260/280 UV 1.8–2.0 Protein carryover
A260/230 UV ≥2.0 Salt and organic carryover
Purity & safety Endotoxin LAL ≤0.01 EU/µg (≤0.005 available) Cell viability, innate immune activation, in vivo tolerability
Host cell DNA qPCR ≤5% Immunogenicity and transfection interference
Host cell RNA Fluorescence / gel Non-detectable (≤500 ng) Purity and nuclease sensitivity
Residual protein BCA / UV ≤1% Stability and aggregate formation
Antibiotic residue ELISA <1.125 ng/mL Compatibility with cell therapy manufacturing
Animal-origin components Documentation None used; statement per lot Viral safety and TSE/BSE risk
TSE / BSE Certificate Compliant Global regulatory acceptance
Microbiology Sterility Membrane filtration No growth, 48 h Aseptic release for cell culture use
Mycoplasma Culture / qPCR Negative Regulatory requirement for cell-based processes

The paperwork is part of the product.

A plasmid that cannot be defended in an IND is not a GMP plasmid. Every lot ships with the records your CMC team, your vector CDMO and your reviewer will ask for — in the format they expect.

Cell banks

MCB / WCB establishment

Two-tier banking with identity, purity, viability and stability qualification, plus release summaries.

Lot records

Batch records & QA disposition

Executed GMP batch records, deviation and CAPA records, and QA release by lot.

Release

CoA, CoC and release package

Certificate of analysis and conformity, with raw data traceability to instrument level.

Analytics

Method qualification & validation

Qualified and validated methods with transferable protocols for your QC lab or CDMO.

Stability

ICH Q1A stability program

Real-time and accelerated conditions, with annual commitment and protocol-based pull points.

Filing

DMF / eCTD Module 3 support

Authoring and review support for plasmid sections referenced in your IND, BLA or MAA.

Transfer

Tech transfer package

Process description, SOPs, equipment list, method protocols and on-site support if required.

Governance

Quality & supply agreements

QTA/MSA, formal change control, audit access and long-term supply planning.

Programs supported across FDA, EMA, NMPA, PMDA and MFDS submissions, from pre-IND through commercial supply.

Quick Inquiry